Company Performance - CytomX Therapeutics reported break-even quarterly earnings per share, surpassing the Zacks Consensus Estimate of a loss of $0.06, and improved from a loss of $0.08 per share a year ago, resulting in an earnings surprise of +100.00% [1] - The company posted revenues of $18.66 million for the quarter ended June 2025, exceeding the Zacks Consensus Estimate by 2.07%, although this represents a decline from year-ago revenues of $25.11 million [2] - Over the last four quarters, CytomX has consistently surpassed consensus EPS and revenue estimates [2] Stock Performance - CytomX Therapeutics shares have increased approximately 110.7% since the beginning of the year, significantly outperforming the S&P 500's gain of 7.9% [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the market in the near future [6] Future Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.07 on revenues of $15.9 million, with a breakeven expectation on revenues of $98.28 million for the current fiscal year [7] - The outlook for the Medical - Biomedical and Genetics industry, where CytomX operates, is favorable, ranking in the top 41% of over 250 Zacks industries, suggesting potential for outperformance [8]

Group 1 - EOG Resources reported quarterly earnings of $2.32 per share, exceeding the Zacks Consensus Estimate of $2.21 per share, but down from $3.16 per share a year ago, representing an earnings surprise of +4.98% [1] - The company posted revenues of $5.48 billion for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 0.30%, but down from $6.03 billion year-over-year [2] - EOG Resources has surpassed consensus EPS estimates in all four of the last quarters, while it has only topped consensus revenue estimates once in the same period [2] Group 2 - The stock has underperformed the market, losing about 4.9% since the beginning of the year compared to the S&P 500's gain of 7.9% [3] - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to those expectations [4] - The current consensus EPS estimate for the coming quarter is $2.40 on revenues of $5.85 billion, and for the current fiscal year, it is $10.05 on revenues of $23.33 billion [7] Group 3 - The Zacks Industry Rank indicates that the Oil and Gas - Exploration and Production - United States sector is currently in the bottom 28% of over 250 Zacks industries, which may impact stock performance [8] - The estimate revisions trend for EOG Resources was mixed ahead of the earnings release, resulting in a Zacks Rank 3 (Hold) for the stock, suggesting it is expected to perform in line with the market [6]

Core Insights - Dynavax Technologies reported quarterly earnings of $0.14 per share, exceeding the Zacks Consensus Estimate of $0.12 per share, and showing an increase from $0.08 per share a year ago, resulting in an earnings surprise of +16.67% [1] - The company achieved revenues of $95.44 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 8.99%, compared to $73.79 million in the same quarter last year [2] - Dynavax Technologies has outperformed consensus EPS estimates three times over the last four quarters and has topped consensus revenue estimates two times in the same period [2] Financial Performance - The company experienced a significant earnings surprise of -466.67% in the previous quarter, where it was expected to post earnings of $0.03 per share but instead reported a loss of $0.11 [1] - The current consensus EPS estimate for the upcoming quarter is $0.15, with expected revenues of $96.97 million, while the estimate for the current fiscal year is -$0.41 on revenues of $331.45 million [7] Market Position - Dynavax Technologies shares have declined approximately 12.4% since the beginning of the year, contrasting with the S&P 500's gain of 7.9% [3] - The Zacks Rank for Dynavax Technologies is currently 4 (Sell), indicating expectations of underperformance in the near future [6] Industry Context - The Medical - Biomedical and Genetics industry, to which Dynavax belongs, is currently ranked in the top 41% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]

Group 1 - Cresco Labs Inc. reported a quarterly loss of $0.05 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.04, and improved from a loss of $0.16 per share a year ago, indicating a surprise of -25.00% [1] - The company posted revenues of $163.62 million for the quarter ended June 2025, missing the Zacks Consensus Estimate by 0.15%, and down from $184.36 million in the same quarter last year [2] - Cresco Labs Inc. shares have declined approximately 24.5% since the beginning of the year, contrasting with the S&P 500's gain of 7.9% [3] Group 2 - The earnings outlook for Cresco Labs Inc. is uncertain, with current consensus EPS estimates at -$0.03 on revenues of $169.47 million for the upcoming quarter and -$0.11 on revenues of $675.98 million for the current fiscal year [7] - The Zacks Industry Rank places the Medical - Products sector in the bottom 37% of over 250 Zacks industries, suggesting that the industry outlook could significantly impact stock performance [8] Group 3 - The estimate revisions trend for Cresco Labs Inc. was mixed ahead of the earnings release, resulting in a Zacks Rank 3 (Hold), indicating expected performance in line with the market [6] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]

Company Performance - Cars.com reported quarterly earnings of $0.41 per share, missing the Zacks Consensus Estimate of $0.46 per share, but showing an increase from $0.38 per share a year ago, representing an earnings surprise of -10.87% [1] - The company posted revenues of $178.74 million for the quarter ended June 2025, missing the Zacks Consensus Estimate by 0.59%, and showing a slight decrease from year-ago revenues of $178.89 million [2] - Over the last four quarters, Cars.com has not surpassed consensus EPS estimates and has topped consensus revenue estimates only once [2] Stock Performance - Cars.com shares have declined approximately 24.2% since the beginning of the year, contrasting with the S&P 500's gain of 7.9% [3] - The stock's immediate price movement will largely depend on management's commentary during the earnings call [3] Future Outlook - The current consensus EPS estimate for the coming quarter is $0.48 on revenues of $181.96 million, and for the current fiscal year, it is $1.75 on revenues of $725.04 million [7] - The estimate revisions trend for Cars.com was favorable ahead of the earnings release, resulting in a Zacks Rank 2 (Buy) for the stock, indicating expected outperformance in the near future [6] Industry Context - The Internet - Commerce industry, to which Cars.com belongs, is currently in the bottom 34% of over 250 Zacks industries, suggesting that the industry outlook can significantly impact stock performance [8]

分组1 - PENN Entertainment reported quarterly earnings of $0.1 per share, exceeding the Zacks Consensus Estimate of a loss of $0.04 per share, and showing improvement from a loss of $0.18 per share a year ago, resulting in an earnings surprise of +350.00% [1] - The company posted revenues of $1.77 billion for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 1.73%, compared to revenues of $1.66 billion in the same quarter last year [2] - Over the last four quarters, PENN Entertainment has surpassed consensus EPS estimates three times, but has only topped consensus revenue estimates once [2] 分组2 - PENN Entertainment shares have declined approximately 14.1% since the beginning of the year, contrasting with the S&P 500's gain of 7.9% [3] - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to those expectations [4] - The current consensus EPS estimate for the upcoming quarter is -$0.02 on revenues of $1.73 billion, and for the current fiscal year, it is $0.73 on revenues of $6.94 billion [7] 分组3 - The Zacks Industry Rank indicates that the Gaming industry is currently in the bottom 42% of over 250 Zacks industries, suggesting that the industry's outlook can significantly impact stock performance [8] - Another company in the same industry, GDEV Inc., is expected to report quarterly earnings of $0.26 per share, reflecting a year-over-year decline of -67.9%, with revenues projected at $89.35 million, down 15.6% from the previous year [9]

Core Insights - CorMedix (CRMD) reported quarterly earnings of $0.28 per share, exceeding the Zacks Consensus Estimate of $0.20 per share, and showing a significant improvement from a loss of $0.25 per share a year ago [1] - The company achieved revenues of $39.74 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 7.94%, compared to revenues of $0.81 million in the same quarter last year [2] - CorMedix has consistently outperformed consensus EPS and revenue estimates over the last four quarters [2] Earnings Performance - The earnings surprise for the recent quarter was +40.00%, following a previous surprise of +20% when actual earnings were $0.30 per share against an expectation of $0.25 [1][2] - The current consensus EPS estimate for the upcoming quarter is $0.22, with expected revenues of $39.89 million, and for the current fiscal year, the EPS estimate is $0.97 on revenues of $159.01 million [7] Stock Performance and Outlook - CorMedix shares have increased approximately 47.5% since the beginning of the year, significantly outperforming the S&P 500's gain of 7.9% [3] - The company's favorable estimate revisions trend prior to the earnings release has resulted in a Zacks Rank 1 (Strong Buy), indicating expectations for continued outperformance in the near future [6] Industry Context - The Medical - Biomedical and Genetics industry, to which CorMedix belongs, is currently ranked in the top 41% of over 250 Zacks industries, suggesting a positive outlook for stocks within this sector [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]

Group 1 - Regenxbio reported a quarterly loss of $1.38 per share, which was worse than the Zacks Consensus Estimate of a loss of $1.13, and compared to a loss of $1.05 per share a year ago, indicating a significant earnings surprise of -22.12% [1] - The company posted revenues of $21.36 million for the quarter ended June 2025, missing the Zacks Consensus Estimate by 21.16%, and this represents a decline from year-ago revenues of $22.3 million [2] - Over the last four quarters, Regenxbio has surpassed consensus EPS estimates only once, indicating challenges in meeting market expectations [2] Group 2 - The stock has gained approximately 6.5% since the beginning of the year, underperforming compared to the S&P 500's gain of 7.9% [3] - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The current consensus EPS estimate for the upcoming quarter is $0.29 on revenues of $102.44 million, while for the current fiscal year, it is -$0.56 on revenues of $293.35 million [7] Group 3 - The Zacks Industry Rank places the Medical - Biomedical and Genetics sector in the top 41% of over 250 Zacks industries, suggesting a favorable environment for stocks in this sector [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5] - The current estimate revisions trend for Regenxbio is mixed, resulting in a Zacks Rank 3 (Hold), suggesting the stock is expected to perform in line with the market in the near future [6]

D-WAVE QUANTUM shares have added about 109.3% since the beginning of the year versus the S&P 500's gain of 7.9%. What's Next for D-WAVE QUANTUM? While D-WAVE QUANTUM has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the comin ...

Financial Performance - Hyatt Hotels reported quarterly earnings of $0.68 per share, exceeding the Zacks Consensus Estimate of $0.66 per share, but down from $1.53 per share a year ago, indicating an earnings surprise of +3.03% [1] - The company posted revenues of $1.81 billion for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 3.85%, compared to $1.7 billion in the same quarter last year [2] - Over the last four quarters, Hyatt has surpassed consensus EPS estimates three times and topped consensus revenue estimates two times [2] Stock Performance and Outlook - Hyatt Hotels shares have declined approximately 13.3% since the beginning of the year, while the S&P 500 has gained 7.9% [3] - The company's earnings outlook will be crucial for future stock performance, with current consensus EPS estimates at $0.56 for the upcoming quarter and $2.24 for the current fiscal year [4][7] Industry Context - The Hotels and Motels industry, to which Hyatt belongs, is currently ranked in the bottom 10% of over 250 Zacks industries, which may negatively impact stock performance [8] - H World Group, another company in the same industry, is expected to report quarterly earnings of $0.56 per share, reflecting a year-over-year change of +21.7% [9]